{
    "nctId": "NCT03209518",
    "briefTitle": "Special Drug Use Surveillance of Leuprorelin for Injection Kit 22.5 mg in \"Premenopausal Breast Cancer\"",
    "officialTitle": "Special Drug Use Surveillance of Leuplin PRO for Injection Kit 22.5 mg in \"Premenopausal Breast Cancer\"",
    "overallStatus": "COMPLETED",
    "conditions": "Premenopausal Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 312,
    "primaryOutcomeMeasure": "Percentage of Participants Who Had One or More Adverse Events",
    "eligibilityCriteria": "Inclusion Criteria:\n\n- Participants with premenopausal breast cancer will be included.\n\nExclusion Criteria:\n\n* Participants with a history of hypersensitivity to any ingredients of Leuplin PRO, synthesized LH-RH, or LH-RH analogues\n* Pregnant or potentially pregnant participants and breastfeeding participants",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}